• $16,387.00
    Market Cap
  • -99.67%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2022
12/31/2021
12/31/2020
Income Statement
Total Operating Revenue
1.1M
-65.50%
3.1M
-50.50%
6.2M
N/A
Cost of Revenue
1.6M
-22.32%
2.1M
-35.25%
3.3M
N/A
Gross Profit
-1.4M
+34.77%
-1.0M
-134.70%
3.0M
N/A
Sales and Marketing Expense
4.1M
-35.22%
6.3M
N/A
N/A
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
459,072
-8.00%
499,000
-1.72%
507,731
N/A
Total Operating Expenses
4.1M
-35.22%
6.3M
-39.54%
10.4M
N/A
Operating Profit
-5.5M
-25.42%
-7.3M
-1.82%
-7.5M
N/A
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
-53,680
-38.05%
-86,645
-33.13%
-129,569
N/A
Interest Income and Expense and Net
-53,680
-38.05%
-86,645
-33.13%
-129,569
N/A
Total Nonoperating Income and Expense
320,579
+23.61%
259,337
+100.15%
129,569
N/A
Income before Taxes
-5.1M
-27.22%
-7.1M
-6.91%
-7.6M
N/A
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-5.1M
-27.22%
-7.1M
-6.91%
-7.6M
N/A
Net Income from Continuing Operations Applicable to Common
-5.5M
-23.68%
-7.3M
-4.33%
-7.6M
N/A
Basic EPS and Net Income
-0.13
-23.53%
-0.17
-5.56%
-0.18
N/A
Diluted EPS and Net Income
-0.13
-23.53%
-0.17
-5.56%
-0.18
N/A
Basic Weighted Average Shares
41.6M
-4.04%
43.4M
+1.86%
42.6M
N/A
Diluted Weighted Average Shares
41.6M
-4.04%
43.4M
+1.86%
42.6M
N/A
Balance Sheet
Cash and Cash Equivalents
55,273
-88.53%
481,763
+347.35%
107,693
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
55,273
-88.53%
481,763
+347.35%
107,693
N/A
Total Current Assets
3.5M
-12.60%
4.0M
-39.28%
6.7M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
1.5M
N/A
Property and Plant and Equipment and Net
2.8M
-27.25%
3.9M
-14.15%
4.5M
N/A
Total Long-Term Assets
136,209
-40.42%
228,611
-94.91%
4.5M
N/A
Total Assets
6.8M
-20.97%
8.6M
-30.71%
12.4M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
3,278
-94.70%
61,836
-74.48%
242,330
N/A
Total Current Liabilities
3.2M
+43.38%
2.2M
-41.12%
3.8M
N/A
Total Long-Term Debt
150,000
-19.61%
186,592
-33.01%
278,527
N/A
Total Long-Term Liabilities
414,182
-31.07%
600,909
-40.43%
1.0M
N/A
Total Liabilities
7.4M
+96.17%
3.8M
-20.76%
4.8M
N/A
Retained Earnings
-39.5M
+16.34%
-33.9M
+27.24%
-26.7M
N/A
Total Stockholders Equity
-606,277
-112.56%
4.8M
-36.90%
7.6M
N/A
Total Shares Outstanding
41.6M
-0.005%
41.6M
-9.09%
45.8M
N/A
Cash Flow
Cash from Operating Activities
-3.9M
-18.16%
-4.8M
+60.18%
-3.0M
N/A
Capital Expenditures
10,334
-87.13%
80,289
-8.80%
88,038
N/A
Cash from Investing Activities
18,456
+122.99%
-80,289
-8.80%
-88,038
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
3.4M
-33.84%
5.2M
+149.50%
2.1M
N/A
Financials Ratio
Gross Margin
-54.62%
-274.32%
31.33%
-34.04%
47.51%
N/A
Operating Margin
-514.01%
+116.20%
-237.75%
+98.34%
-119.87%
N/A
Return on Assets
-66.84%
-0.68%
-67.29%
+18.00%
-57.03%
N/A
Return on Equity
-243.84%
+115.16%
-113.33%
+48.09%
-76.53%
N/A
Revenue Growth
-65.50%
+29.71%
-50.50%
+245.42%
-14.62%
N/A
Current Ratio
1.12
-39.05%
1.83
+3.12%
1.77
N/A
Cash Ratio
0.02
-91.98%
0.22
+659.93%
0.03
N/A
Debt-to-Equity Ratio
-0.25
-590.87%
0.05
-24.38%
0.07
N/A
Debt-to-Assets Ratio
0.02
-21.80%
0.03
-31.19%
0.04
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow